Eloralintide 10 mg

Eloralintide (LY3841136)

Selective Amylin Receptor Agonist | Weight Management Support

Eloralintide is a selective amylin receptor agonist designed to promote satiety, help control appetite, reduce food intake, and support weight management through the amylin pathway, which works differently from GLP-1.

What is Eloralintide?

Eloralintide, also known as LY3841136, is a long-acting amylin receptor agonist developed by Eli Lilly. It is designed to act primarily on AMY1R (Amylin Receptor 1).

Amylin is a naturally occurring hormone involved in regulating satiety and food intake.

Simply put, when the amylin system sends signals to the brain, the body recognizes that enough food has been consumed. This helps increase feelings of fullness and reduces the desire to continue eating.

Eloralintide is designed to mimic this pathway, potentially helping people feel full sooner, manage appetite more effectively, and reduce daily calorie intake, which may support long-term weight management.

Key Benefits of Eloralintide

• Promotes feelings of fullness after eating

• Helps control hunger and appetite

• May help reduce daily food intake

• Supports weight loss and weight management

• Works through the amylin pathway, which differs from GLP-1

• Designed to selectively target AMY1R

• Features a long-acting molecular structure

• Designed for once-weekly administration in clinical development

• Being evaluated both as a standalone treatment and in combination with Tirzepatide

Mechanism of Action

Eloralintide works by activating AMY1R, an amylin receptor involved in regulating satiety and eating behavior.

When AMY1R is activated, signals associated with fullness are transmitted to areas of the brain involved in regulating hunger and food intake.

As a result, individuals may feel full sooner, require smaller portions to feel satisfied, and experience a reduced desire to eat.

By helping reduce food intake, Eloralintide may lower overall daily calorie consumption, which is an important mechanism for supporting weight management.

How is Eloralintide Different from Cagrilintide?

Both Eloralintide and Cagrilintide target the amylin system, but their receptor activity differs.

Eloralintide is designed to be more selective for AMY1R, demonstrating approximately 11–12 times greater selectivity for AMY1R than for CTR and AMY3R.

The concept behind this selective design is to maintain the effects associated with satiety and appetite control while limiting activation of other receptors that may contribute to gastrointestinal effects.

This Selective Amylin Receptor Agonist profile is one of the key characteristics that distinguishes Eloralintide.

How is Eloralintide Different from Tirzepatide?

Eloralintide and Tirzepatide both target appetite and weight management, but they work through different biological pathways.

Tirzepatide
Acts through GIP and GLP-1 receptors.

Eloralintide
Acts through the amylin pathway, primarily targeting AMY1R.

In simple terms, both may help reduce food intake, but they send satiety and appetite-related signals through different systems in the body.

For this reason, Eloralintide is also being evaluated in combination with Tirzepatide to determine whether targeting complementary pathways may provide additional weight-management benefits.

Molecular Information

Name
Eloralintide

Development Code
LY3841136

Length
37 Amino Acids

Type
Selective AMY1R Amylin Receptor Agonist

Structure
Modified Human Amylin Analog

Eloralintide is structurally modified from human amylin and includes modifications that enhance albumin binding in the bloodstream, allowing the compound to remain in the body for an extended period.

This long-acting profile supports its development for once-weekly administration.

Who May Benefit?

Eloralintide is currently being evaluated in adults with obesity or overweight.

Its mechanism is particularly focused on:

• Managing hunger throughout the day

• Controlling appetite

• Reducing excessive food intake

• Managing daily calorie intake

• Supporting weight loss and weight management

• Supporting healthier body composition

What You May Notice

Early effects associated with Eloralintide's mechanism may include increased feelings of fullness and reduced appetite.

With continued administration under controlled clinical protocols, changes in food intake, body weight, and body composition may become noticeable.

Individual results can vary depending on factors such as diet, physical activity, energy expenditure, metabolic health, and individual response.

Potential Side Effects

The most commonly reported adverse effects have primarily involved the gastrointestinal system, including:

• Nausea

• Gastrointestinal discomfort

• Fatigue in some individuals

The frequency and severity of these effects may vary between individuals.

Important Information

Eloralintide is an investigational compound and is not currently FDA-approved for weight management. Therefore, there is currently no approved general-use dosing or self-administration protocol.

The information provided here is for general informational purposes regarding Eloralintide, its characteristics, and mechanism of action. It is not intended as medical advice, diagnosis, treatment, or dosing guidance.

Long-term efficacy and safety are still being evaluated, and individual results may vary.